Patents by Inventor Sangryeol Ryu

Sangryeol Ryu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric endolysin LYS109 with antimicrobial activity against
    Patent number: 11827912
    Abstract: The present invention relates to chimeric endolysin Lys109 which effectively controls Staphylococcus aureus, wherein the endolysin Lys109 of the present invention has a novel amino acid sequence that has not been conventionally studied. Endolysin Lys109 of the present invention can be used as a biological regulator capable of effectively inhibiting a wide range of Staphylococcus aureus and a biofilm produced thereby. In addition, endolysin Lys109 can kill Staphylococcus aureus without regard for resistance to conventional antibiotics, and thus can be widely used for treatment of diseases caused by Staphylococcus aureus infection. Moreover, endolysin Lys109 can also be used to resolve medical problems caused by Staphylococcus aureus which has antibiotic resistance.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: November 28, 2023
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Sangryeol Ryu, Bokyung Son
  • CHIMERIC ENDOLYSIN LYS109 WITH ANTIMICROBIAL ACTIVITY AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20220228135
    Abstract: The present invention relates to chimeric endolysin Lys109 which effectively controls Staphylococcus aureus, wherein the endolysin Lys109 of the present invention has a novel amino acid sequence that has not been conventionally studied. Endolysin Lys109 of the present invention can be used as a biological regulator capable of effectively inhibiting a wide range of Staphylococcus aureus and a biofilm produced thereby. In addition, endolysin Lys109 can kill Staphylococcus aureus without regard for resistance to conventional antibiotics, and thus can be widely used for treatment of diseases caused by Staphylococcus aureus infection. Moreover, endolysin Lys109 can also be used to resolve medical problems caused by Staphylococcus aureus which has antibiotic resistance.
    Type: Application
    Filed: April 21, 2020
    Publication date: July 21, 2022
    Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Sangryeol RYU, Bokyung SON
  • BACTERIOPHAGES FOR INHIBITING BACTERIA
    Publication number: 20220184155
    Abstract: This disclosure describes bacteriophages that may be used to improve the selective isolation of Campylobacter from foods or to control antibiotic-resistant bacteria, or both. This disclosure further describes methods of using those bacteriophages.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 16, 2022
    Inventors: Byeonghwa Jeon, Sangryeol Ryu, Jinshil Kim